Ultragenyx Pharmaceutical Inc. (RARE) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 33 analysts31.3% Below Target
RARE trades 31.3% below Wall Street's consensus target of $47.11.
Current Price$35.87
Average Target$47.11
Target
Current
Low$26.00
Median$43.00
High$67.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+26.0%
(High Growth)
Analyst Spread87.0%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes RARE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 33 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
RARE Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Ultragenyx Pharmaceutical Inc. (RARE) has a Wall Street consensus price target of $47.11, based on estimates from 33 covering analysts. With the stock currently trading at $35.87, this represents a potential upside of +31.3%. The company has a market capitalization of $3.53B.
Analyst price targets range from a low of $26.00 to a high of $67.00, representing a 87% spread in expectations. The median target of $43.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RARE trades at a trailing P/E of -6.2x. Analysts expect EPS to grow +26.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+25.8%
Industry Consensus
Avg Forward P/E
35.1x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BMRNBioMarin Pharmaceutical Inc. | $11.6B | $60.35 | $89.21 | +47.8% | Buy | 12.2x | 41 |
 SRPTSarepta Therapeutics, Inc. | $2.1B | $19.79 | $25.14 | +27.0% | Buy | 5.6x | 54 |
 IONSIonis Pharmaceuticals, Inc. | $14.3B | $86.33 | $106.50 | +23.4% | Buy | — | 32 |
 ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $10.9B | $368.60 | $336.40 | -8.7% | Buy | 48.0x | 17 |
 RYTMRhythm Pharmaceuticals, Inc. | $7.8B | $114.46 | $139.57 | +21.9% | Buy | — | 20 |
 LGNDLigand Pharmaceuticals Incorporated | $6.4B | $319.43 | $265.33 | -16.9% | Buy | 35.3x | 17 |
 PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
 NTLAIntellia Therapeutics, Inc. | $2.0B | $17.43 | $26.13 | +49.9% | Buy | — | 39 |
RARE — Frequently Asked Questions
Quick answers to the most common questions about buying RARE stock.
What is the RARE stock price target for 2026?
The consensus Wall Street price target for RARE is $47.11, representing 31.3% upside from the current price of $35.87. With 33 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is RARE a buy, sell, or hold?
RARE has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $47.11 implies 31.3% upside from current levels.
Is RARE stock overvalued or undervalued?
RARE's current price is $35.87 with a consensus target of $47.11 (31.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can RARE stock go?
The most bullish Wall Street analyst has a price target of $67 for RARE, while the most conservative target is $26. The consensus of $47.11 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RARE stock?
RARE is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RARE stock forecast?
The 12-month RARE stock forecast based on 33 Wall Street analysts shows a consensus price target of $47.11, with estimates ranging from $26 (bear case) to $67 (bull case). The median consensus rating is "Buy".
Should I buy RARE stock?
Wall Street analysts are very optimistic on RARE, with a "Buy" consensus rating and $47.11 price target (31.3% upside). 26 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RARE price targets vary so much?
RARE analyst price targets range from $26 to $67, a 87% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $47.11 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare